US3896813A - Sutures having long-lasting biocidal properties - Google Patents

Sutures having long-lasting biocidal properties Download PDF

Info

Publication number
US3896813A
US3896813A US243425A US24342572A US3896813A US 3896813 A US3896813 A US 3896813A US 243425 A US243425 A US 243425A US 24342572 A US24342572 A US 24342572A US 3896813 A US3896813 A US 3896813A
Authority
US
United States
Prior art keywords
suture
sutures
antibiotic
salt
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US243425A
Inventor
Leonard D Kurtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutures Inc
MTG Divestitures LLC
Original Assignee
Sutures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutures Inc filed Critical Sutures Inc
Priority to US243425A priority Critical patent/US3896813A/en
Priority to ZA724131A priority patent/ZA724131B/en
Priority to GB2934072A priority patent/GB1401842A/en
Priority to IT12754/72A priority patent/IT968120B/en
Priority to DE2232731A priority patent/DE2232731A1/en
Priority to FR7229855A priority patent/FR2179691B1/fr
Priority to JP47090525A priority patent/JPS4914800A/ja
Priority to DE2320468A priority patent/DE2320468A1/en
Application granted granted Critical
Publication of US3896813A publication Critical patent/US3896813A/en
Assigned to PFIZER HOSPITAL PRODUCTS GROUP INC. reassignment PFIZER HOSPITAL PRODUCTS GROUP INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: HOWMEDICA, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • DTEXTILES; PAPER
    • D06TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06MTREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M16/00Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20Targets to be treated
    • A61L2202/26Textiles, e.g. towels, beds, cloths
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45Mixtures of two or more drugs, e.g. synergistic mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow

Definitions

  • ABSTRACT Sutures are provided with long-lasting biocidal properties against both gram-negative and gram-positive bacteria by incorporating substantially water-insoluble salts of an acid antibiotic and a basic antibiotic into the body of the suture.
  • the sutures can be prepared by sequentially impregnating the sutures with aqueous solutions of the respective antibiotics or by first forming the water-soluble salt of the antibiotic and impregnating the suture with an organic solution of the water-insoluble salt.
  • the present invention relates to sutures having longlasting anti-bacterial properties and to methods of providing such sutures.
  • antibiotics have been previously employed to coat or impregnate various textile materials in order to induce therein bactericidal properties.
  • U.S. Pat. No. 2,830,011 to Parker et al except for neomycin such materials have been limited to singleuse purposes and have been discarded or thrown away following such single use. The reason for this was the fact that the antibiotics were not sufficiently stable or substantive and consequently could not remain in active acti-bacterial form therein following cleaning operations prior to reuse. Consequently, use of antibiotics as impregnants has been limited and their commercial acceptance has not been as widespread as their characteristics indicate.
  • biocides should be tenaciously held by the suture to prevent repid leaching and yet the biocide cannot be so intimately held that its anti-bacterial activity is lost.
  • the problem in the art has been to provide feasible techniques to make sutures with long-lasting anti-bacterial properties.
  • Sutures having long-lasting biocidal properties are provided according to the invention by providing uniformily throughout the body of the suture a substantially water-insoluble salt of an acid antibiotic and basic antibiotic.
  • the bactericide is actually incorporated within the body of the suture and is not merely deposited on the surface thereof.
  • the insoluble anti-bacterial salts of the invention comprise a cation of a basic antibiotic and an anion of an acid antibiotic and have been found surprisingly to provide long-lasting effectiveness against both gram-positive and gram-negative bacteria despite their high water-insolubility.
  • the solubility in water at C of the antibiotic salts of the invention does not exceed about 4.0 mg. per ml. and preferably does not exceed 2.0 mg. per ml.
  • the particularly preferred antibiotic salts of the invention have a solubility of less than 1.0 mg. per ml. yet exhibit extraordinary effectiveness against both gram-positive and gram-negative bacteria.
  • biocidal materials are substantially insoluble in water, they are generally soluble in organic solvents (e.g. methyl and ethyl alcohol, ether, ethyl acetate, benzene, chloroform, acetone, dimethylsulfoxide and other common organic solvents) and can generally be dissolved in aqueous organic solvents.
  • a persistent reservoir of a water-insoluble agent is established within the suture which offers broad spectrum antibiotic activity.
  • Suitable basic antibiotics which may be used to form the substantially water-insoluble salts of the invention include those classified as polypeptides, sugars and bases.
  • polypeptides may be mentioned bacitracin, polymyxins, tyrothricin and vancomycin.
  • Sugars include neomycin, erythromycin, streptomycin, vancomycin and nystatin.
  • Bases include cycloserine, tetracycline, aureomycin and terramycin.
  • the preferred basic antibiotics are gentamicin and polymixin B.
  • Suitable acid antibiotics are penicillins, fumagillin and cephalosporins such as cephalolexin, cephaloglycin, cephaloridine and cephalothin.
  • penicillins as used herein means acid antibiotics which are structurally o-substituted penicillanic acids such as Penicillins G, N, O and V, nafcillin, methicillin. oxacillin and the like.
  • Both the cation of the basic antibiotic and the anion of the acid antibiotic are conveniently provided in aqueous solutions of the respective antibiotics or their water-soluble addition salts.
  • Mineral acid salts of the basic antibiotic are particularly good sources for the cations whereas the alkali metal, e.g. Na and K salts of the acid antibiotic are preferred sources for the anions.
  • Preparation of the substantially water-insoluble salt is simply accomplished by combining these aqueous solutions of the cations and anions to form the salt which will precipitate.
  • the long'lasting anti-bacterial materials mentioned above can, according to the invention, be provided in situ in any suture material which is swellable but not itself particularly soluble in the solution employed for the impregnation.
  • the substrate is simply contacted with a solution of the water-insoluble anti-bacterial salt in a solvent such as an organic solvent or which is also a swelling agent for the suture.
  • a solvent such as an organic solvent or which is also a swelling agent for the suture.
  • the sol vent swells the suture and the solvent plus salt will penetrate into the body of the suture material.
  • the solvent can then be removed by evaporation, extraction, etc., and the salt will remain incorporated into the body of the suture.
  • This impregnation procedure offers a convenient method of introducing a water-insoluble bactericide into the body of the suture that remains surprisingly effective against both gram-positive and gramnegative bacteria.
  • this method offers the additional advantages of enabling precise determination of the concentrations of each antibiotic present in the suture.
  • An alternative method of introducing the insoluble germicide into the suture comprises depositing the salt in situ by sequentially treating the suture with a solution of the acid antibiotic and a solution of the basic antibiotic solution or vice versa.
  • This method has been surprisingly found to incorporate higher concentrations of the second added antibiotic in a single impregnation than can be obtained by an impregnation with the same antibiotic alone, that is, without the previously added antibiotic.
  • the solutions will include a swelling agent which enhances impregnation into the suture.
  • the swelling agent may be water or an organic solvent.
  • the solutions can be heated to aid impregnation provided that the biocides are not destroyed by such heat.
  • EXAMPLE I immersed in a 10 percent aqueous solution of gentamicin sulfate maintained at approximately F for about 8 to 24 hours. After this treatment the suture is removed from the oven and blotted to remove excess water. The suture is then vacuum dried at lF for 16 to 24 hours and its dry weight taken to determine the mg/yd pickup.
  • the resulting suture is then subjected to a second treatment comprising immersing the suture in a percent aqueous solution of sodium oxacillin maintained at 100F for a period of 2-4 hours.
  • a second treatment comprising immersing the suture in a percent aqueous solution of sodium oxacillin maintained at 100F for a period of 2-4 hours.
  • the drying process described above is repeated and the mg/yd pickup is calculated.
  • the aqueous solution employed in the above treatments are each capable of swelling the silk suture and an intra-fibrillar precipitate of gentamicin oxacillinate is thus formed well within the body of the suture.
  • the precipitate is then held tenaciously within the body of the suture such that it is very resistant to the leaching action of body fluids and this provides a persistant reservoir for both the gentamicin and the oxacillin antibiotics. It is also resistant to repeated washings and thus provides sutures which are persistently effective against gram negative and gram positive bacteria even after re peated washings.
  • Example I The procedure of Example I is repeated substituting polymyxin B sulfate for gentamicin sulfate to provide a silk suture having incorporated therein polymyxin B oxacillinate. The results of the treatments are summarized in the following Table 2.
  • Example III The procedure of Example I is repeated substituting sodium cephalothin for sodium oxacillin to provide a suture having incorporated therein polymyxin B cephalothinate. The results of the impregnations are summarized below in Table 3:
  • Substantially water-insoluble polymyxin B oxacillinate is first prepared by mixing together at room temperature a 10 percent aqueous solution of polymyxin B sulfate and a 10 percent aqueous solution of sodium oxacillin. The resulting precipitate of polymyxin B oxacillinate is recovered and dissolved in /25 ethyl alcohol/water.
  • Gentamicin oxacillinate is prepared as described in Example III by substituting gentamicin sulfate for polym xin B sulfate.
  • a size 2/0 braided Dacron polyester (polyethylene terephthalate) surgical suture having incorporated therein gentamicin oxacillinate is prepared by following the impregnation procedure described in Example IV.
  • the suture material can be natural, such as silk, gut and cotton, or synthetic such as regenerated cellulose, cellulose esters, polyamides, polyacrylics, polyesters, polyvinyls and polyolefins.
  • anti-bacterial salts of the invention have virtually unmeasurable solubility in water.
  • sutures provided with these salts exhibit longlasting anti-bacterial activity. Therefore, it is considered appropriate to include within the meaning of substantially insoluble, those materials which have a solubility in water which ranges from substantially undetectable to about 4.0 mg per ml at 25C.
  • the amount of insoluble compound provided in the suture can vary widely and large amounts can be provided by repeating the impregnation process. Antibacterial activity is achieved with very small amounts of material. In general, the amount of antibacterial material in the suture will depend upon the intended use, and in general, up to 25 or even 50 percent by weight based on the suture material is contemplated. The minimum amount of biocide is largely a matter of choice, but trace amounts and amounts as low as l.() percent or 0.1 percent by weight, based on the weight of the suture, are effective.
  • anti-bacterial material can be provided in some cases, it is generally not practical to do so since lesser amounts achieve the desired persistent anti-bacterial action and the preferred amount of anti-bacterial material for sutures is therefore between 0.1 and percent by weight based on the weight of the suture material.
  • sutures provided with insoluble biodical salts according to the invention is demonstrated by placing sutures prepared according to the invention as shown in the foregoing examples, in contact with organism such as Bacillus subtilis, Escherichia coli or Staphlococcus aureus. Even after repeated washings, the area around a silk suture containing the bactericides of the invention will remain clear of the organism whereas no inhibition thereof is noted when placing a similarly washed thread originally treated with an individual antibiotic in the same environment. Similarly, the persistent antibacterial nature of the suture is illustrated by in vivo testings in mice. Silk sutures treated according to the invention, after being implanted in mice for five days, show no growth of organisms when removed and placed in a culture medium.
  • the sutures to which the invention relates are, with the exception of the long-lasting biocides incorporated therein, of conventional configuration and materials.
  • the sutures are generally sterilized and may be attached to suture needles in the usual manner and packaged in a sterile condition.
  • insoluble salts formed from gentamicin and penicillins particularly the synthetic penicillins effective against gram-positive bacteria such as nafcillin, methicillin and oxacillin.
  • the gentamicin cation is effective against pseudomonads and proteus and the synthetic penicillins are effective against penicillin resistant strains of staphglcocci.
  • the antimicrobial results are excellent and there is substantially no tissue reaction.
  • a surgical suture having long-lasting bactericidal properties comprising a suture strand having incorporated substantially uniformly within the body thereof throughout its length an effective amount of a substantially water-insoluble salt of a penicillin and a basic antibiotic selected from the group consisting of gentamicin and a polymyxin, said substantially water-insoluble salt being held tenaciously in said suture strand to provide a long-lasting source of both said antibiotics.
  • substantially water-insoluble salt is a'salt of gentamicin and oxacillin.
  • substantially water-insoluble salt is a salt of polymyxin and oxacillin.
  • suture is of a material selected from silk and gut.

Abstract

Sutures are provided with long-lasting biocidal properties against both gram-negative and gram-positive bacteria by incorporating substantially water-insoluble salts of an acid antibiotic and a basic antibiotic into the body of the suture. The sutures can be prepared by sequentially impregnating the sutures with aqueous solutions of the respective antibiotics or by first forming the water-soluble salt of the antibiotic and impregnating the suture with an organic solution of the waterinsoluble salt.

Description

United States Patent [191 Kurtz 1 1 *July 29, 1975 1 SUTURES HAVING LONG-LASTING BIOCIDAL PROPERTIES [75] Inventor: Leonard D. Kurtz, Woodmere, N.Y.
[73] Assignee: Sutures, Inc., Coventry, Conn.
[ Notice: The portion of the term of this patent subsequent to Feb. 15, 1989, has been disclaimed.
[22] Filed: Apr. 12, 1972 211 Appl. No.: 243,425
Related U.S. Application Data [63] Continuation-in-part of Ser. No. 851,739, Aug. 20, 1969, abandoned, which is a continuation-in-part of Ser. No. 648,247, June 23, 1967, abandoned.
3,069,320 12/1962 Vitalis 424/181 3,235,556 12/1966 Wakeman et al..... 260/286 3,328,409 6/1967 Wakeman et a1. 260/286 3,388,704 6/1968 Kurtz 128/3355 FOREIGN PATENTS OR APPLICATIONS 788,968 1/1958 United Kingdom 424/329 OTHER PUBLICATIONS The Merck Index, Eighth Edition; Merck & Co., Inc., Rahway, NJ. USA, pgs. 485, 771, 790 & 848.
Primary Examiner-Frederick E. Waddell Attorney, Agent, or FirmLarson, Taylor and Hinds [57] ABSTRACT Sutures are provided with long-lasting biocidal properties against both gram-negative and gram-positive bacteria by incorporating substantially water-insoluble salts of an acid antibiotic and a basic antibiotic into the body of the suture. The sutures can be prepared by sequentially impregnating the sutures with aqueous solutions of the respective antibiotics or by first forming the water-soluble salt of the antibiotic and impregnating the suture with an organic solution of the water-insoluble salt.
8 Claims, N0 Drawings SUTURES HAVING LONG-LASTING BIOCIDAL PROPERTIES This is a continuation in part of my US. application Ser. No. 851,739 filed Aug. 20, 1969, now abandoned, which in turn is a continuation in part of application Ser. No. 648,247, filed June 23, 1967, now abandoned.
The present invention relates to sutures having longlasting anti-bacterial properties and to methods of providing such sutures.
There have been several attempts to provide antibacterial material in sutures. For example, US. Pat. Nos. 86 l ,23 l and 2,751,910 relate to providing germicidal sutures.
Also, antibiotics have been previously employed to coat or impregnate various textile materials in order to induce therein bactericidal properties. As noted in U.S. Pat. No. 2,830,011 to Parker et al, however, except for neomycin such materials have been limited to singleuse purposes and have been discarded or thrown away following such single use. The reason for this was the fact that the antibiotics were not sufficiently stable or substantive and consequently could not remain in active acti-bacterial form therein following cleaning operations prior to reuse. Consequently, use of antibiotics as impregnants has been limited and their commercial acceptance has not been as widespread as their characteristics indicate.
it is thus desirable that the biocides should be tenaciously held by the suture to prevent repid leaching and yet the biocide cannot be so intimately held that its anti-bacterial activity is lost. The problem in the art has been to provide feasible techniques to make sutures with long-lasting anti-bacterial properties.
Sutures having long-lasting biocidal properties are provided according to the invention by providing uniformily throughout the body of the suture a substantially water-insoluble salt of an acid antibiotic and basic antibiotic. The bactericide is actually incorporated within the body of the suture and is not merely deposited on the surface thereof. The insoluble anti-bacterial salts of the invention comprise a cation of a basic antibiotic and an anion of an acid antibiotic and have been found surprisingly to provide long-lasting effectiveness against both gram-positive and gram-negative bacteria despite their high water-insolubility. In general, the solubility in water at C of the antibiotic salts of the invention does not exceed about 4.0 mg. per ml. and preferably does not exceed 2.0 mg. per ml. in fact, the particularly preferred antibiotic salts of the invention have a solubility of less than 1.0 mg. per ml. yet exhibit extraordinary effectiveness against both gram-positive and gram-negative bacteria. While the biocidal materials are substantially insoluble in water, they are generally soluble in organic solvents (e.g. methyl and ethyl alcohol, ether, ethyl acetate, benzene, chloroform, acetone, dimethylsulfoxide and other common organic solvents) and can generally be dissolved in aqueous organic solvents.
Thus, in accordance with the present invention a persistent reservoir of a water-insoluble agent is established within the suture which offers broad spectrum antibiotic activity.
Suitable basic antibiotics which may be used to form the substantially water-insoluble salts of the invention include those classified as polypeptides, sugars and bases. Among the polypeptides may be mentioned bacitracin, polymyxins, tyrothricin and vancomycin. Sugars include neomycin, erythromycin, streptomycin, vancomycin and nystatin. Bases include cycloserine, tetracycline, aureomycin and terramycin. The preferred basic antibiotics are gentamicin and polymixin B.
Illustrative of suitable acid antibiotics are penicillins, fumagillin and cephalosporins such as cephalolexin, cephaloglycin, cephaloridine and cephalothin. The term penicillins as used herein means acid antibiotics which are structurally o-substituted penicillanic acids such as Penicillins G, N, O and V, nafcillin, methicillin. oxacillin and the like.
Both the cation of the basic antibiotic and the anion of the acid antibiotic are conveniently provided in aqueous solutions of the respective antibiotics or their water-soluble addition salts. Mineral acid salts of the basic antibiotic are particularly good sources for the cations whereas the alkali metal, e.g. Na and K salts of the acid antibiotic are preferred sources for the anions. Preparation of the substantially water-insoluble salt is simply accomplished by combining these aqueous solutions of the cations and anions to form the salt which will precipitate.
The long'lasting anti-bacterial materials mentioned above can, according to the invention, be provided in situ in any suture material which is swellable but not itself particularly soluble in the solution employed for the impregnation. The substrate is simply contacted with a solution of the water-insoluble anti-bacterial salt in a solvent such as an organic solvent or which is also a swelling agent for the suture. In this manner the sol vent swells the suture and the solvent plus salt will penetrate into the body of the suture material. The solvent can then be removed by evaporation, extraction, etc., and the salt will remain incorporated into the body of the suture. This impregnation procedure offers a convenient method of introducing a water-insoluble bactericide into the body of the suture that remains surprisingly effective against both gram-positive and gramnegative bacteria. In addition, this method offers the additional advantages of enabling precise determination of the concentrations of each antibiotic present in the suture. An alternative method of introducing the insoluble germicide into the suture comprises depositing the salt in situ by sequentially treating the suture with a solution of the acid antibiotic and a solution of the basic antibiotic solution or vice versa. This method has been surprisingly found to incorporate higher concentrations of the second added antibiotic in a single impregnation than can be obtained by an impregnation with the same antibiotic alone, that is, without the previously added antibiotic. In either case, the solutions will include a swelling agent which enhances impregnation into the suture. The swelling agent may be water or an organic solvent. The solutions can be heated to aid impregnation provided that the biocides are not destroyed by such heat.
The invention is further illustrated in the examples which follow. 7
EXAMPLE I immersed in a 10 percent aqueous solution of gentamicin sulfate maintained at approximately F for about 8 to 24 hours. After this treatment the suture is removed from the oven and blotted to remove excess water. The suture is then vacuum dried at lF for 16 to 24 hours and its dry weight taken to determine the mg/yd pickup.
The resulting suture is then subjected to a second treatment comprising immersing the suture in a percent aqueous solution of sodium oxacillin maintained at 100F for a period of 2-4 hours. The drying process described above is repeated and the mg/yd pickup is calculated.
The results of the above described treatments are set forth in the following Table I.
The aqueous solution employed in the above treatments are each capable of swelling the silk suture and an intra-fibrillar precipitate of gentamicin oxacillinate is thus formed well within the body of the suture. The precipitate is then held tenaciously within the body of the suture such that it is very resistant to the leaching action of body fluids and this provides a persistant reservoir for both the gentamicin and the oxacillin antibiotics. It is also resistant to repeated washings and thus provides sutures which are persistently effective against gram negative and gram positive bacteria even after re peated washings.
For comparison, a similar suture is subjected to impregnation with a 10 percent aqueous solution of sodium oxacillin alone. The pick up of oxacillin in the suture is found to be 0.4 mg/yd. Comparing the oxacillin pickup in this suture with that of the method of the present invention shows that the method of the present invention is capable of introducing larger amounts of the second added antibiotic in a single impregnation.
EXAMPLE I] The procedure of Example I is repeated substituting polymyxin B sulfate for gentamicin sulfate to provide a silk suture having incorporated therein polymyxin B oxacillinate. The results of the treatments are summarized in the following Table 2.
Total mg/yd. pickup Comparing the pickup of oxacillin in this example with the pickup of oxacillin by impregnations with a 10 percent aqueous solution of sodium oxacillin shown in Example I demonstrates that sutures having greater amounts of the second added antibiotic can be provided.
EXAMPLE III The procedure of Example I is repeated substituting sodium cephalothin for sodium oxacillin to provide a suture having incorporated therein polymyxin B cephalothinate. The results of the impregnations are summarized below in Table 3:
For comparison, a similar suture is subjected to impregnation with a 10 percent aqueous solution of sodium cephalothin along. The highest level of sodium cephalothin that is incorporated in the suture is 1.0 mg/yd.
EXAMPLE IV Substantially water-insoluble polymyxin B oxacillinate is first prepared by mixing together at room temperature a 10 percent aqueous solution of polymyxin B sulfate and a 10 percent aqueous solution of sodium oxacillin. The resulting precipitate of polymyxin B oxacillinate is recovered and dissolved in /25 ethyl alcohol/water.
20 yards of surgical silk suture size 2/0 is predried in a vacuum oven at F for 3 hours. The dry weight of the suture is determined and it is placed in the saturated solution of polymyxin B oxacillinate for 2 hours. A platform is used to cover precipitate in the treating container in order to avoid surface crust on the suture. The suture is then removed from the solution, the excess solution blotted off and the suture vacuum dried for 16 hours at 100F. The pickup of polymyxin B oxacillinate is found to be 1.2 mg/yd.
EXAMPLE V Gentamicin oxacillinate is prepared as described in Example III by substituting gentamicin sulfate for polym xin B sulfate. A size 2/0 braided Dacron polyester (polyethylene terephthalate) surgical suture having incorporated therein gentamicin oxacillinate is prepared by following the impregnation procedure described in Example IV.
The suture material can be natural, such as silk, gut and cotton, or synthetic such as regenerated cellulose, cellulose esters, polyamides, polyacrylics, polyesters, polyvinyls and polyolefins.
Several of the anti-bacterial salts of the invention have virtually unmeasurable solubility in water. However, sutures provided with these salts exhibit longlasting anti-bacterial activity. Therefore, it is considered appropriate to include within the meaning of substantially insoluble, those materials which have a solubility in water which ranges from substantially undetectable to about 4.0 mg per ml at 25C.
The amount of insoluble compound provided in the suture can vary widely and large amounts can be provided by repeating the impregnation process. Antibacterial activity is achieved with very small amounts of material. In general, the amount of antibacterial material in the suture will depend upon the intended use, and in general, up to 25 or even 50 percent by weight based on the suture material is contemplated. The minimum amount of biocide is largely a matter of choice, but trace amounts and amounts as low as l.() percent or 0.1 percent by weight, based on the weight of the suture, are effective. Although more anti-bacterial material can be provided in some cases, it is generally not practical to do so since lesser amounts achieve the desired persistent anti-bacterial action and the preferred amount of anti-bacterial material for sutures is therefore between 0.1 and percent by weight based on the weight of the suture material.
The persistent anti-bacterial activity of sutures provided with insoluble biodical salts according to the invention is demonstrated by placing sutures prepared according to the invention as shown in the foregoing examples, in contact with organism such as Bacillus subtilis, Escherichia coli or Staphlococcus aureus. Even after repeated washings, the area around a silk suture containing the bactericides of the invention will remain clear of the organism whereas no inhibition thereof is noted when placing a similarly washed thread originally treated with an individual antibiotic in the same environment. Similarly, the persistent antibacterial nature of the suture is illustrated by in vivo testings in mice. Silk sutures treated according to the invention, after being implanted in mice for five days, show no growth of organisms when removed and placed in a culture medium.
The sutures to which the invention relates are, with the exception of the long-lasting biocides incorporated therein, of conventional configuration and materials. The sutures are generally sterilized and may be attached to suture needles in the usual manner and packaged in a sterile condition.
Particularly good results have been achieved with insoluble salts formed from gentamicin and penicillins, particularly the synthetic penicillins effective against gram-positive bacteria such as nafcillin, methicillin and oxacillin. The gentamicin cation is effective against pseudomonads and proteus and the synthetic penicillins are effective against penicillin resistant strains of staphglcocci. When provided in a suture according to the present invention, the antimicrobial results are excellent and there is substantially no tissue reaction.
It is claimed:
1. A surgical suture having long-lasting bactericidal properties comprising a suture strand having incorporated substantially uniformly within the body thereof throughout its length an effective amount of a substantially water-insoluble salt of a penicillin and a basic antibiotic selected from the group consisting of gentamicin and a polymyxin, said substantially water-insoluble salt being held tenaciously in said suture strand to provide a long-lasting source of both said antibiotics.
2. The surgical suture of claim 1 wherein the basic antibiotic is gentamicin.
3. The surgical suture of claim 1 wherein the basic antibiotic is a polymyxin.
4. The surgical suture of claim 1 wherein the basic antibiotic is polymyxin B.
5. The surgical suture of claim 4 wherein the penicillin is oxacillin.
6. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a'salt of gentamicin and oxacillin.
7. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a salt of polymyxin and oxacillin.
8. The surgical suture of claim 1 wherein the suture is of a material selected from silk and gut.

Claims (8)

1. A SURGICAL SUTURE HAVING LONG-LASTING BACTERICIDAL PROPERTIES COMPRISING A SUTURE STRAND HAVING INCORPORATED SUBSTANTIALLY UNIFORMLY WITHIN THE BODY THEREOF THROUGHOUT ITS LENGTH AN EFFECTIVE AMOUNT OF A SUBSTANTIALLY WATER-INSOLUBLE SALT OF A PENICILLIN AND A BASIC ANTIBIOTIC SELECTED FROM THE GROUP CONSISTING OF GENTAMICIN AND A POLYMYXIN, SAID SUBSTANTIALLY WATER-INSOLUBLE SALT BEING HELD TENACIOUSLY IN SAID SUTURE STRAND TO PROVIDE A LONG-LASTING SOURCE OF BOTH SAID ANTIBIOTICS.
2. The surgical suture of claim 1 wherein the basic antibiotic is gentamicin.
3. The surgical suture of claim 1 wherein the basic antibiotic is a polymyxin.
4. The surgical suture of claim 1 wherein the basic antibiotic is polymyxin B.
5. The surgical suture of claim 4 wherein the penicillin is oxacillin.
6. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a salt of gentamicin and oxacillin.
7. The surgical suture of claim 1 wherein the substantially water-insoluble salt is a salt of polymyxin and oxacillin.
8. The surgical suture of claim 1 wherein the suture is of a material selected from silk and gut.
US243425A 1967-06-23 1972-04-12 Sutures having long-lasting biocidal properties Expired - Lifetime US3896813A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US243425A US3896813A (en) 1967-06-23 1972-04-12 Sutures having long-lasting biocidal properties
ZA724131A ZA724131B (en) 1972-04-12 1972-06-15 Sutures having long-lasting biocidal properties
GB2934072A GB1401842A (en) 1972-04-12 1972-06-22 Sutures having long-lasting ciocidal properties
IT12754/72A IT968120B (en) 1972-04-12 1972-06-28 THREADS FOR SUTURES WITH LONG-LASTING BIOCIDAL PROPERTIES
DE2232731A DE2232731A1 (en) 1972-04-12 1972-07-04 SURGICAL SUTURE MATERIAL WITH LONG-LASTING Germicidal Properties
FR7229855A FR2179691B1 (en) 1972-04-12 1972-08-21
JP47090525A JPS4914800A (en) 1972-04-12 1972-09-11
DE2320468A DE2320468A1 (en) 1972-04-12 1973-04-21 SURGICAL SUTURE

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64824767A 1967-06-23 1967-06-23
US85173969A 1969-08-20 1969-08-20
US243425A US3896813A (en) 1967-06-23 1972-04-12 Sutures having long-lasting biocidal properties

Publications (1)

Publication Number Publication Date
US3896813A true US3896813A (en) 1975-07-29

Family

ID=27399662

Family Applications (1)

Application Number Title Priority Date Filing Date
US243425A Expired - Lifetime US3896813A (en) 1967-06-23 1972-04-12 Sutures having long-lasting biocidal properties

Country Status (1)

Country Link
US (1) US3896813A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024871A (en) * 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
US4542169A (en) * 1983-12-12 1985-09-17 Rohm And Haas Company Biomedical devices containing isothiazolones to control bacteria growth
US4708870A (en) * 1985-06-03 1987-11-24 E. I. Du Pont De Nemours And Company Method for imparting antimicrobial activity from acrylics
WO1988000062A1 (en) * 1986-07-04 1988-01-14 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny I Ligature material
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
WO1989009627A1 (en) * 1988-04-07 1989-10-19 Edward Shanbrom Non-thrombogenic intravascular catheter coated with polymyxin
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US5009229A (en) * 1989-12-06 1991-04-23 Medtronic, Inc. Steroid eluting intramuscular lead
US5086787A (en) * 1989-12-06 1992-02-11 Medtronic, Inc. Steroid eluting intramuscular lead
EP0607284A1 (en) * 1991-10-10 1994-07-27 Menlo Care Inc. Therapeutic agent in hydrophilic matrix
US5584877A (en) * 1993-06-25 1996-12-17 Sumitomo Electric Industries, Ltd. Antibacterial vascular prosthesis and surgical suture
US6416549B1 (en) 1999-07-19 2002-07-09 Sulzer Carbomedics Inc. Antithrombogenic annuloplasty ring having a biodegradable insert

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861231A (en) * 1906-05-03 1907-07-23 Johnson & Johnson Surgical ligature.
US2743268A (en) * 1952-07-12 1956-04-24 Lilly Co Eli Erythromycin-penicillin
US2751910A (en) * 1953-06-25 1956-06-26 Edward L Howes Sutures
US2830011A (en) * 1957-02-07 1958-04-08 American Cyanamid Co Textile fabrics containing neomycin
US3069320A (en) * 1958-11-18 1962-12-18 American Cyanamid Co Synergistic sanitizing process with neomycin and selected cationic surface active quaternary ammonium salts
US3235556A (en) * 1963-03-05 1966-02-15 Millmaster Onyx Corp Alkyl isoquinolinium salts of aromatic carboxylic acids
US3328409A (en) * 1964-02-10 1967-06-27 Millmaster Onyx Corp Quaternary salts of dimer acids
US3388704A (en) * 1964-10-02 1968-06-18 Sutures Inc Microbiocidal sutures containing quaternary ammonium compounds and method for making

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861231A (en) * 1906-05-03 1907-07-23 Johnson & Johnson Surgical ligature.
US2743268A (en) * 1952-07-12 1956-04-24 Lilly Co Eli Erythromycin-penicillin
US2751910A (en) * 1953-06-25 1956-06-26 Edward L Howes Sutures
US2830011A (en) * 1957-02-07 1958-04-08 American Cyanamid Co Textile fabrics containing neomycin
US3069320A (en) * 1958-11-18 1962-12-18 American Cyanamid Co Synergistic sanitizing process with neomycin and selected cationic surface active quaternary ammonium salts
US3235556A (en) * 1963-03-05 1966-02-15 Millmaster Onyx Corp Alkyl isoquinolinium salts of aromatic carboxylic acids
US3328409A (en) * 1964-02-10 1967-06-27 Millmaster Onyx Corp Quaternary salts of dimer acids
US3388704A (en) * 1964-10-02 1968-06-18 Sutures Inc Microbiocidal sutures containing quaternary ammonium compounds and method for making

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024871A (en) * 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
US5021241A (en) * 1983-10-14 1991-06-04 Sumitomo Pharmaceuticals Company, Limited Long-term sustained-release preparation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
US4542169A (en) * 1983-12-12 1985-09-17 Rohm And Haas Company Biomedical devices containing isothiazolones to control bacteria growth
US4708870A (en) * 1985-06-03 1987-11-24 E. I. Du Pont De Nemours And Company Method for imparting antimicrobial activity from acrylics
WO1988000062A1 (en) * 1986-07-04 1988-01-14 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny I Ligature material
US4875479A (en) * 1986-07-04 1989-10-24 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki Sutural material
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
WO1989009627A1 (en) * 1988-04-07 1989-10-19 Edward Shanbrom Non-thrombogenic intravascular catheter coated with polymyxin
US5009229A (en) * 1989-12-06 1991-04-23 Medtronic, Inc. Steroid eluting intramuscular lead
US5086787A (en) * 1989-12-06 1992-02-11 Medtronic, Inc. Steroid eluting intramuscular lead
EP0607284A1 (en) * 1991-10-10 1994-07-27 Menlo Care Inc. Therapeutic agent in hydrophilic matrix
EP0607284A4 (en) * 1991-10-10 1997-06-04 Menlo Care Inc Therapeutic agent in hydrophilic matrix.
US5584877A (en) * 1993-06-25 1996-12-17 Sumitomo Electric Industries, Ltd. Antibacterial vascular prosthesis and surgical suture
US6416549B1 (en) 1999-07-19 2002-07-09 Sulzer Carbomedics Inc. Antithrombogenic annuloplasty ring having a biodegradable insert

Similar Documents

Publication Publication Date Title
US3896813A (en) Sutures having long-lasting biocidal properties
DE102006001954B4 (en) Antiseptic alginate preparation, process for their preparation, and their use
US3896812A (en) Sutures having long-lasting biocidal properties
US4612337A (en) Method for preparing infection-resistant materials
US6436422B1 (en) Antibiotic hydrophilic polymer coating
US5534288A (en) Infection-resistant surgical devices and methods of making them
US3642003A (en) Sutures having long-lasting germicidal properties
US6866859B2 (en) Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties
US5722992A (en) Implant, its use in surgery and processes for the production thereof
US4581028A (en) Infection-resistant materials and method of making same through use of sulfonamides
US5707736A (en) Products having anti-microbial activity
DE69931159T2 (en) ANTIMICROBIAL COMPOSITIONS CONTAINING TURROLIDINE, CITRIC ACID AND SODIUM ZITRATE
US20120328682A1 (en) Particles incorporating antimicrobial agents
HUT74669A (en) Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections
EP0647452B1 (en) Infection-resistant surgical devices and methods of making them
CN109331219A (en) A kind of chitosan liquid dressing
EP0852148B1 (en) Products having anti-microbial activity
CA1083961A (en) Neomycin fatty acid salt containing surgical sutures
RU2749636C1 (en) Method for obtaining antibacterial material
DE2232731A1 (en) SURGICAL SUTURE MATERIAL WITH LONG-LASTING Germicidal Properties
Gravens et al. The antibacterial effect of treating sutures with silver
JPH02307915A (en) Antibacterial fiber product
Thomas et al. Improvements in medicated tulle dressings
DE876446C (en) Hemostatic sponge
WO2001037670A2 (en) Antimicrobial hook and loop fastener

Legal Events

Date Code Title Description
AS Assignment

Owner name: PFIZER HOSPITAL PRODUCTS GROUP INC.

Free format text: CHANGE OF NAME;ASSIGNOR:HOWMEDICA, INC.;REEL/FRAME:004471/0589

Effective date: 19840624